Renshen-Baidu-San restores epithelial-immune crosstalk and drives type 2 immune repair in ulcerative colitis: an integrated multi-omics study - PubMed
6 hours ago
- #multi-omics
- #Renshen-Baidu-San
- #ulcerative colitis
- Renshen-Baidu-San (BDS) shows therapeutic effects in ulcerative colitis (UC) by modulating steroid- and lipid-derived metabolites.
- BDS influences pathways like steroid hormone biosynthesis, bile acid turnover, and arachidonic acid metabolism.
- Network pharmacology and molecular docking indicate BDS regulates inflammatory signaling and cellular proliferation.
- Single-cell transcriptomics reveals BDS corrects epithelial-immune dysregulation, targeting Tuft and T-1 cells via NF-κB-TNF-α suppression.
- Colon organoid experiments confirm BDS promotes mucosal repair, crypt recovery, Tuft cell expansion, and a type 2 immune shift with increased IL-4/IL-25 and reduced IL-13.
- BDS treatment alters metabolic pathways, restores epithelial-immune crosstalk, and drives type 2 immune-mediated mucosal repair in UC.